Skip to main content
. 2024 May 1;16(9):1764. doi: 10.3390/cancers16091764

Figure 3.

Figure 3

Overall survival of patients with or without endocrine immune-related adverse events in the entire cohort (A) and depending on the tumor type (B); progression-free survival in patients with or without endocrine immune-related adverse events (C).